Effect of aluminum hydroxide on diflunisal absorption. 1979

R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper

1 The effect of aluminum hydroxide on the oral absorption of diflunisal was studied in healthy subjects. 2 Relative bioavailability of the oral diflunisal dose (500 mg) was estimated by comparison of the areas under plasma concentration versus time curves, and comparison of the amount of drug (unchanged + glucuronides) excreted in the urine. 3 From the AUC-method, a relative bioavailability of 0.60 was calculated. A similar value (F = 0.63) was obtained from the urinary excretion data. 4 The results indicate that co-administration of aluminum hydroxide reduces the bioavailability of oral diflusinal by about 40%.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000536 Aluminum Hydroxide A compound with many biomedical applications: as a gastric antacid, an antiperspirant, in dentifrices, as an emulsifier, as an adjuvant in bacterins and vaccines, in water purification, etc. Hydrated Alumina,Aldrox,Algeldrate,Alhydrogel,Alugel,Amphojel,Basalgel,Brasivil,Dialume,Nephrox,Pepsamer,Rocgel,Alumina, Hydrated,Hydroxide, Aluminum
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012459 Salicylates The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis. Salicylate,Salicylic Acids,Acids, Salicylic
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
August 1976, The Journal of the Arkansas Medical Society,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
March 1990, DICP : the annals of pharmacotherapy,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
October 1958, The New England journal of medicine,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
March 2016, Pulmonary circulation,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
June 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
October 1993, Antimicrobial agents and chemotherapy,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
February 1976, Clinical pharmacology and therapeutics,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
October 1980, Clinical pharmacology and therapeutics,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
January 1952, Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft,
R Verbeeck, and T B Tjandramaga, and A Mullie, and R Verbesselt, and P J de Schepper
July 1956, Schweizerische medizinische Wochenschrift,
Copied contents to your clipboard!